Womvil-I Tablet is a combination anthelmintic medication containing Ivermectin 6 mg and Albendazole 400 mg, indicated for the treatment of a broad spectrum of parasitic infections. Ivermectin acts by binding selectively to glutamate-gated chloride ion channels in nerve and muscle cells of parasites, leading to paralysis and death of the parasites. Albendazole works by inhibiting microtubule synthesis, thereby impairing glucose uptake and depleting energy stores in susceptible helminths. This synergistic combination is effective against a variety of intestinal and tissue parasites, including strongyloidiasis, onchocerciasis, ascariasis, trichuriasis, hookworm infections, and neurocysticercosis. Womvil-I is typically administered orally as a single dose or as prescribed by a healthcare professional, with dosage adjustments based on the type and severity of infection. It is contraindicated in patients with known hypersensitivity to either component and should be used cautiously in pregnant or lactating women. Common adverse effects may include mild gastrointestinal disturbances, dizziness, and headache. Patients are advised to follow the prescribed regimen and consult their physician if symptoms persist or adverse reactions occur. Womvil-I Tablet offers an effective therapeutic option for comprehensive management of helminthic infections, improving patient outcomes through its dual-action formulation.